<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02639923</url>
  </required_header>
  <id_info>
    <org_study_id>Wolf-7</org_study_id>
    <nct_id>NCT02639923</nct_id>
  </id_info>
  <brief_title>The Clinical Relevance of Micro RNAs in Mild Traumatic Brain Injury</brief_title>
  <acronym>mRNA</acronym>
  <official_title>The Clinical Relevance of Micro RNAs in Mild Traumatic Brain Injury A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harald Wolf, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Scientific Fund of the Mayor of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the early serum measurement (&lt;6h after injury) of
      mRNA miR Let-7i, miR-16 and miR-92 in patients with MHI and intracranial traumatic lesions
      (CCT pos.) as compared to those in patients with MHI without intracranial traumatic lesions
      (CCT neg.).

      S100B serum levels will be measured in both groups. The usual risk factors for the occurrence
      of an intracranial hematoma (diagnostic algorithm) will be recorded. Additionally, a group of
      healthy individuals will serve as a control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients and Methods

      The investigators plan to include 60 patients with minor head injury (MHI) admitted to our
      hospital within one year (1-2 each week):

      1. 30 patients in the CCT pos. group, i.e. patients with an intracranial hematoma on
      emergency CT scan. 2. 30 patients with MHI in the CCT neg. group, i.e. patients without an
      intracranial traumatic lesion on emergency CT-scan. 3. Additionally, 30 healthy volunteers
      will be included.

      Patients with multiple injuries i.e. polytraumatized patients, patients with severe traumatic
      brain injury, patients with open fractures and fractures of the long bones, as well as
      pregnant patients and patients &lt;18 years, are excluded from the study.

      Patients with a GCS (Glascow Coma Scale) of 13-15 are usually able to consent to be enrolled
      in the clinical trial. Generally, their reasoning and judgment is not impaired.

      The objective of the study is to compare 3 groups on the microRNA serum levels.

      The investigators plan to draw blood from a peripheral catheter in the patients of groups 1
      and 2 (within 6 hours) after arrival at the hospital together with the routine laboratory
      investigations. Additionally, blood will be obtained from healthy volunteers (group 3).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hypothesis: Significant elevation or decrease of the mRNAs miR Let-7i, miR-16 and miR-92 among the study groups</measure>
    <time_frame>6 hours</time_frame>
    <description>non of the measured biomarker shows a significant difference between the 3 study groups</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Brain Injuries, Traumatic</condition>
  <arm_group>
    <arm_group_label>Minor head injury CCT pos. group</arm_group_label>
    <description>Tbi patients with acute lesion on early cranial computed tomography. Patients consent to have 7ml peripheral blood to be drawn.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minor head injury CCT neg. group</arm_group_label>
    <description>Tbi patients without acute lesion on early cranial computed tomography. Patients consent to have 7ml peripheral blood to be drawn.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group (healthy volunteers)</arm_group_label>
    <description>Volunteers without history, signs or symptoms of acute traumatic injuries. Volunteers consent to have 7ml peripheral blood to be drawn.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Drawing of 7ml peripheral blood</intervention_name>
    <description>puncture peripheral vein</description>
    <arm_group_label>Minor head injury CCT pos. group</arm_group_label>
    <arm_group_label>Minor head injury CCT neg. group</arm_group_label>
    <arm_group_label>Control Group (healthy volunteers)</arm_group_label>
    <other_name>7ml serum</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      7ml serum are drawn from peripheral blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We plan to include 60 patients with minor head injury (MHI) GCS 13-15 admitted to our
        hospital within one year (1-2 each week).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  TBI with GCS 13-15

        Exclusion Criteria:

          -  Patients with multiple injuries i.e. polytraumatized patients, patients with severe
             traumatic brain injury, patients with open fractures and fractures of the long bones,
             as well as pregnant patients and patients &lt;18 years, are excluded from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald Wolf, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department for Trauma Surgery, Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harald Wolf, M.D.</last_name>
    <phone>+43140400</phone>
    <phone_ext>59010</phone_ext>
    <email>harald.wolf@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harald Widhalm, M.D.</last_name>
    <phone>+43140400</phone>
    <phone_ext>59010</phone_ext>
    <email>harald.widhalm@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Wolf, M.D.</last_name>
      <phone>+43140400</phone>
      <phone_ext>5959</phone_ext>
      <email>harald.wolf@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Harald K Widhalm, M.D.</last_name>
      <phone>+43140400</phone>
      <phone_ext>59010</phone_ext>
      <email>harald.widhalm@meduniwien.ac.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <results_reference>
    <citation>Balakathiresan N, Bhomia M, Chandran R, Chavko M, McCarron RM, Maheshwari RK. MicroRNA let-7i is a promising serum biomarker for blast-induced traumatic brain injury. J Neurotrauma. 2012 May 1;29(7):1379-87. doi: 10.1089/neu.2011.2146. Epub 2012 Apr 13.</citation>
    <PMID>22352906</PMID>
  </results_reference>
  <results_reference>
    <citation>Sharma A, Chandran R, Barry ES, Bhomia M, Hutchison MA, Balakathiresan NS, Grunberg NE, Maheshwari RK. Identification of serum microRNA signatures for diagnosis of mild traumatic brain injury in a closed head injury model. PLoS One. 2014 Nov 7;9(11):e112019. doi: 10.1371/journal.pone.0112019. eCollection 2014.</citation>
    <PMID>25379886</PMID>
  </results_reference>
  <results_reference>
    <citation>Redell JB, Moore AN, Ward NH 3rd, Hergenroeder GW, Dash PK. Human traumatic brain injury alters plasma microRNA levels. J Neurotrauma. 2010 Dec;27(12):2147-56. doi: 10.1089/neu.2010.1481. Epub 2010 Nov 23.</citation>
    <PMID>20883153</PMID>
  </results_reference>
  <results_reference>
    <citation>Redell JB, Zhao J, Dash PK. Altered expression of miRNA-21 and its targets in the hippocampus after traumatic brain injury. J Neurosci Res. 2011 Feb;89(2):212-21. doi: 10.1002/jnr.22539. Epub 2010 Dec 8.</citation>
    <PMID>21162128</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2015</study_first_submitted>
  <study_first_submitted_qc>December 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2015</study_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Harald Wolf, MD</investigator_full_name>
    <investigator_title>Oberarzt Dr. Harald Wolf</investigator_title>
  </responsible_party>
  <keyword>TBI</keyword>
  <keyword>microRNA</keyword>
  <keyword>S-100B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Brain Concussion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

